Drug intelligence / Profile preview

VDA-005

Development stage: Preclinical
Lead developer: viDA Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Ophthalmic

Overview

VDA-005 is a preclinical drug candidate developed by viDA Therapeutics. It acts as a granzyme B (GRB) modulator, targeting the GRB enzyme. The primary therapeutic area under investigation for VDA-005 is eye diseases. As of the latest update, its highest development status is preclinical. The mechanism of action involves modulation of granzyme B activity, which may play a role in tissue remodeling and inflammation associated with ocular conditions[1].

Targets

GZMB (Granzyme B)

Beyond the preview

Go deeper on VDA-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDA-005.

Explore the full profile